Discover our latest publication, which helps predict the survival of cancer patients treated with immune checkpoint inhibitors.
Here is our latest publication, titled A novel gut-restricted small molecule TLR2 agonist enhances immune checkpoint inhibitor efficacy in a preclinical mouse fibrosarcoma tumor model.
Here is our latest publication, titled Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer.
In this collaborative work, researchers from Institut Bergonié, Institut Gustave Roussy, and Explicyte, demonstrated that presence of APAP in plasma from cancer patients before they undergo immunotherapy was independently associated with a worse clinical outcome.
Read our latest peer-reviewed publication, titled Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Discover our latest study, titled Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Discover our latest article, published in Frontiers in Immunology.
Here is our latest publication, titled Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.
Here is our latest publication, titled Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE).
Discover our latest publication, titled CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells.
Read our latest publication, titled Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1.
Read our latest publication, titled Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance